#1
#1 out of 1176.4K est. views
health14h ago
Major breakthrough in vaccine development for deadly virus with 75% fatality rate
- Oxford's Nipah vaccine moves to Phase II trials in Bangladesh, enrolling 306 healthy adults aged 18 to 55.
- Phase I results showed 51 participants completed one year of follow-up, with results expected soon.
- Nipah virus has no approved vaccine or treatment and can be fatal in up to 75% of cases, posing pandemic risk.
- The vaccine, ChAdOx1 NipahB, is being developed by Oxford scientists for Phase II in collaboration with CEPI and ICDDR,B.
- Nipah is carried by fruit bats and can spread to humans via contaminated date palm sap and other routes.
- Oxford Vaccine Group leads the phase II trial as part of an international collaboration to improve pandemic preparedness.
- CEPI funds the Nipah vaccine development to support global protection against emerging diseases.
- The Nipah virus outbreaks have occurred in Malaysia, Bangladesh and India, with bat reservoirs identified.
- Oxford’s pursuit of Nipah vaccines reflects long-term investment in pandemic preparedness.
- Experts expect the Nipah vaccine study results to inform development of countermeasures against related viruses.
Vote 0